Ozempic (GLP-1) — Tennessee Litigation
The Ozempic Litigation, Explained
Two consolidated federal proceedings, a September 2026 expert hearing, and state deadlines that vary — here is where the litigation stands.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Partners
Matthew T. Marin & Stefanie A. Murphy
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.
Tennessee’s deadline is the story here: one year for most injury claims, the shortest window in the country alongside Kentucky’s, against tenth-in-the-nation prescription volume — nearly 87,000 Medicaid GLP-1 fills in 2024. The cases consolidate normally: MDL 3094 for stomach injuries, MDL 3163 for NAION, before Judge Karen S. Marston in the Eastern District of Pennsylvania. The federal cases are explained on our main Ozempic litigation page.
Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island and South Carolina, representing injured people and families nationwide. The firm’s mass-tort practice is directed from its Charleston, South Carolina office. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. Marin & Murphy Law Firm is not licensed to practice law in Tennessee. This page is provided for informational purposes and does not constitute an offer to represent any Tennessee resident. The firm does not accept Tennessee legal matters; inquiries from Tennessee residents are referred to attorneys licensed in Tennessee.
Three Tennessee districts under one transfer rule
Tennessee files through the Eastern, Middle, and Western Districts of Tennessee, and the Judicial Panel on Multidistrict Litigation consolidates all of it: GLP-1 stomach-injury cases into MDL 3094, NAION cases into MDL 3163, both before Judge Karen S. Marston in the Eastern District of Pennsylvania. The dockets stood at 4,082 and 278 pending cases in the November 2026 JPML report; no verdict or settlement has issued in either.
A Tennessee case, up close: seven prescriptions, one statutory count
No official count exists of these filings by state, so we track actual Tennessee cases from the court record. On July 20, 2026, a Tennessee resident filed Thouin v. Novo Nordisk, No. 2:26-cv-05016 (E.D. Pa.) — a 12-page short form complaint on the public docket, direct-filed into MDL 3094 with the Eastern District of Tennessee designated as its Original Venue — the home court the case is set up to return to for trial, subject to the challenges the Direct Filing Order preserves. Direct filing let the case enter the MDL immediately rather than wait for a JPML transfer order.
The filing alleges Ozempic use across seven discrete periods between 2020 and 2025 and checks gastroparesis along with other gastrointestinal harm from July 2025 from the form’s list. Of the master complaint’s sixteen counts, it checks exactly one: Count XIII, the state product-liability count, pleaded under the Tennessee Products Liability Act, Tenn. Code §§ 29-28-101 through 29-28-108 — the same statute the master complaint pleads for Tennessee in its state-law inventory. As in Kansas, Connecticut, and Michigan, the state’s product liability act is an exclusive remedy that folds the common-law theories into one statutory claim; the master complaint does not separately plead Tennessee’s consumer-protection statute in Count X, so this case’s single checkbox is the whole of it. Deemed answered and denied on filing, with no individual answer from Novo Nordisk ever appearing on this docket. The form’s mechanics are on our short form complaint page.
As always: one plaintiff’s pleading, drawn from the public record, its allegations unproven and disputed. No court has ruled on the merits of any GLP-1 injury claim. Seven separate prescription periods over five years is not unusual in the record. The deadline that governed this filing is covered next.
One year. Tennessee’s window is the nation’s tightest.
Tennessee gives most injury claimants one year — tied for the shortest period in America. Whatever nuance the accrual rules add, the practical instruction is uniform: if a Tennessee GLP-1 injury is in your history, the dates review cannot wait. Citations below.
Tennessee: top-ten volume, shortest window
The combination defines Tennessee: at least 57,766 Ozempic prescriptions through Medicaid in 2024 — tenth nationally — with at least 16,575 more for Mounjaro and 5,671 for Wegovy (CMS State Drug Utilization Data), against the nation’s shortest filing window. CDC 2023 age-adjusted rates: 12.7% diabetes, 38.0% obesity. Counts are Medicaid floors.
| Medication | TN Medicaid prescriptions (2024) | Amount reimbursed |
|---|---|---|
| Ozempic (semaglutide) | 57,766+ | $54,444,189+ |
| Trulicity (dulaglutide) | 3,966+ | $3,725,327+ |
| Mounjaro (tirzepatide) | 16,575+ | $17,228,401+ |
| Wegovy (semaglutide) | 5,671 | $7,415,067 |
| Rybelsus (semaglutide) | 2,471+ | $2,324,763+ |
| Zepbound (tirzepatide) | 365+ | $375,741+ |
Exactly what Tennessee law says about timing
Tennessee has one of the shortest deadlines in the country: one year for personal-injury claims (Tenn. Code Ann. § 28-3-104), softened only by a discovery rule that starts the clock when you discover, or reasonably should discover, the injury and its cause. Tennessee courts generally measure the one-year wrongful-death period from the underlying injury rather than the death itself — an unusually harsh rule — and the suit is brought by the surviving spouse or personal representative (§§ 20-5-106, 20-5-107). Tennessee also has a product-liability statute of repose (§ 29-28-103). If Tennessee is your state, have your dates reviewed immediately. Federal cases filed in any of Tennessee’s federal districts are transferred to the consolidated GLP-1 proceedings for pretrial work. Both extensions and shortcuts exist in the statutes — nothing but a review of your specific dates settles the question.
Nearby: Ozempic lawsuit information for Kentucky, Georgia, Alabama, North Carolina, Arkansas, and Mississippi — or browse every state.
Who may qualify
- Stomach injuries (gastroparesis or gastric obstruction): use of brand-name Ozempic, Wegovy, or Rybelsus (not compounded or generic semaglutide); a diagnosis confirmed by objective testing such as a gastric emptying study, made while taking the medication or within about 30 days of stopping; a related emergency-room visit or hospital admission; and a diagnosis made before December 31, 2024.
- NAION (sudden optic-nerve vision loss): use of brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound; an actual NAION diagnosis made during or after use; and some degree of permanent vision impairment.
- Criteria evolve, and near-miss situations are often worth reviewing with a lawyer licensed in your state.
Common questions
How widespread is GLP-1 use in Tennessee?
Tenth in the nation: Tennessee Medicaid filled over 86,000 GLP-1 prescriptions in 2024 (CMS data), Ozempic leading with Mounjaro second. The CDC’s 2023 age-adjusted rates — 12.7% diabetes, 38.0% obesity — run well above national medians, and other payers push exposure higher.
Do Tennessee Ozempic cases stay in Tennessee?
No: filings from Tennessee’s Eastern, Middle, and Western Districts consolidate via the JPML into MDL 3094 (stomach injuries) or MDL 3163 (NAION) in the Eastern District of Pennsylvania. Remand to Tennessee follows only for cases unresolved after pretrial.
Is there an Ozempic lawsuit in Tennessee?
Yes — Tennesseans’ claims are consolidated in MDL 3094 (stomach injuries) and MDL 3163 (NAION vision loss) before Judge Karen S. Marston in the Eastern District of Pennsylvania.
What is the deadline to file in Tennessee?
One year for most injury claims — the tightest window on this site, and reason to treat every week as material. The statutory detail below is conservative by design; the urgent step is a review of your dates, now.
Has anyone received an Ozempic settlement?
No. As of November 2026 there are no settlements and no verdicts in any GLP-1 injury lawsuit. Anyone quoting settlement dollar amounts is speculating.
Do I sue my doctor?
No. These lawsuits are against the drug manufacturers — Novo Nordisk and Eli Lilly — not against your prescribing doctor or your pharmacy.
Sources
- JPML MDL statistics report, November 2026 (MDL 3094; MDL 3163)
- JPML Transfer Order, In re Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094 (Feb. 2, 2024)
- JPML Transfer Order, MDL No. 3163 (Dec. 15, 2025)
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone’s injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber.
Attorney Advertising.
This page is attorney advertising and is for informational purposes only; it is not legal or medical advice. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship.
More on the Ozempic (GLP-1) litigation
- Ozempic lawsuit overview (hub)
- Ozempic & GLP-1 lawsuit tracker
- Mounjaro lawsuit
- Wegovy lawsuit
- Ozempic lawyer: what an attorney does, costs, how to choose
- Ozempic lawsuit payout per person
- The September 2026 expert hearing
- MDL 3163: the vision-loss court
- Gastroparesis: the stomach-injury track
- NAION: the vision-loss track
- The gastric emptying study, explained
- U.S. vs. EU warning divergence
- Verdicts & settlements ledger